[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100396839":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":31,"locations":30,"responsibleParty":40,"collaborators":44,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":30,"eligibilityCriteria":71,"healthyVolunteers":67,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":30,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":30,"overallStatus":84,"whyStopped":30,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":30},{"fullName":5,"class":6},"First Affiliated Hospital of Guangxi Medical University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"IC＋CCRT＋Toripalimab＋Endostar","EXPERIMENTAL","Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg\u002Fm2 d1,8; DDP 80mg\u002Fm2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg\u002Fm2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy\u002F30-33f, 5d\u002Fw, 6-7 w; Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles; Endostar: 7.5 mg\u002Fm2\u002Fd, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles.",[13],"Drug: Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy",{"label":15,"type":16,"description":17,"interventionNames":18},"IC＋CCRT","ACTIVE_COMPARATOR","Three cycles of induction chemotherapy with GP regimen (Q3W): Gem 1000 mg\u002Fm2 d1,8; DDP 80mg\u002Fm2 d1, Q3W; IMRT (6-7 weeks, 5 times each week) combined with cisplatin for 2-3 cycles (Q3W): DDP 100 mg\u002Fm2, Q3W, 2-3 cycles; IMRT: GTVnx 70-74Gy\u002F30-33f, 5d\u002Fw, 6-7 w.",[19],"Drug: IC＋CCRT",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy","Toripalimab: 240 mg, Q3W, starting on D1, for totally 12 cycles Endostar: 7.5 mg\u002Fm2\u002Fd, continuous intravenous pumping for 10 days, Q3W, starting on D1, for totally 5 cycles",[9],[27],"JS001",{"type":22,"name":15,"description":15,"armGroupLabels":29,"otherNames":30},[15],null,[32,37],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":36},"rensheng wang, Ph.D","CONTACT","86-771-5356509","13807806008@163.com",{"name":38,"role":34,"phone":35,"phoneExt":30,"email":39},"min kang, Ph.D","km1019@163.com",{"type":41,"investigatorFullName":42,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"PRINCIPAL_INVESTIGATOR","min kang","professor",[45,47,49,51,53,55,57,59,61,63],{"name":46,"class":6},"Shandong Cancer Hospital and Institute",{"name":48,"class":6},"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology",{"name":50,"class":6},"The Affiliated Hospital Of Guizhou Medical University",{"name":52,"class":6},"Xiangya Hospital of Central South University",{"name":54,"class":6},"Jiangxi Provincial Cancer Hospital",{"name":56,"class":6},"Zhejiang Cancer Hospital",{"name":58,"class":6},"Fourth Affiliated Hospital of Guangxi Medical University",{"name":60,"class":6},"LiuZhou People's Hospital",{"name":62,"class":6},"Guilin Medical College",{"name":64,"class":6},"Affiliated Hospital of North Sichuan Medical College","100396839","phase-2-toripalimab-endostar-combined-with-radiotherapy-and-chemotherapy-for-nasopharyngeal-carcinoma-100396839",false,"NCT04447326","Toripalimab, Endostar Combined With Radiotherapy and Chemotherapy for Nasopharyngeal Carcinoma","Randomized Controlled, Multicenter Phase II Clinical Research of Toripalimab (PD-1 Inhibitor) and Endostar Combined With Radiotherapy and Chemotherapy in the Treatment of High-risk Locally Advanced Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. With ECOG score 0-1.\n2. Subjective aged 18-65 years, male or non-pregnant female.\n3. Pathologically diagnosed as nasopharyngeal non-keratinizing carcinoma (differentiated or undifferentiated, i.e., the WHO type II or III).\n4. Stage IVa (8th AJCC\u002FUICC stage) T4 and\u002For N3, untreated patients with nasopharyngeal carcinoma.\n5. Agreeing to provide previously stored tumor tissue samples or perform biopsy to collect tumor tissues, which were sent to the central laboratory for the PD-L1 IHC test.\n6. Hematology: white blood cells ≥ 4000 \u002FμL; neutrophils ≥ 2000 \u002FμL; hemoglobin ≥ 9 g\u002FdL; and platelets ≥ 100000 \u002FμL.\n7. Liver function: ALT and AST lower than the 1.5 times (1.5 × ) the upper limits of normal (ULN); and total bilirubin \\\u003C 1.5 × ULN.\n8. Renal function: serum creatinine \\\u003C 1.5 × ULN.\n9. Patients signing the informed consents, and willing and able to follow the study plan (visit and treatment plan), laboratory tests, and other research procedures.\n\nExclusion criteria:\n\n1. Patients with nasopharyngeal carcinoma with recurrence and distant metastasis.\n2. Pathologically diagnosed as keratinizing squamous cell carcinoma (WHO classification type I).\n3. Patients who had undergone radiotherapy or systemic chemotherapy.\n4. Pregnant or breastfeeding females, or females in fertility period while with no effective contraceptive measures.\n5. Positive for HIV.\n6. Having suffered from other malignant tumors (except for the cured basal cell carcinoma or cervical carcinoma in situ).\n7. Having been treated with inhibitors of immune regulatory points (i.e., CTLA-4, PD-1, PD-L1, etc.).\n8. With complications needing long-term application of immunosuppressive drugs, or systemic or local application of corticosteroids with immunosuppressive doses of comorbidities.\n9. Patients with immunodeficiency diseases, or a history of organ transplantation (including but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, nephritis, hyperthyroidism, hypothyroidism; patients suffering from vitiligo, or asthma in childhood completely relieved, with no need of any intervention after adulthood could be included; and patients with asthma requiring bronchodilators for medical intervention could not be included).\n10. With excessive usage of glucocorticoids within 4 weeks.\n11. Whose laboratory examination values that did not meet the relevant standards within 7 days before participating in the research.\n12. Patients with markedly reduced heart, liver, lung, kidney and\u002For bone marrow functions.\n13. With serious and uncontrolled medical diseases and infections.\n14. Using other test drugs or in other clinical trials.\n15. Refusing or failing to sign the informed consent to participate in the trial.\n16. With other treatment contraindications.\n17. With personality or mental illness, with no or limited civil capacity.\n18. Positive for hepatitis B surface antigen (HBsAg), and peripheral blood hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥ 1000 cps\u002FmL.\n19. Patients positive for the HCV antibody test could only be included in this study with the negative results from the HCV RNA polymerase chain reaction test.\n20. Unable to cooperate with regular follow-up due to psychological, social, family and geographical reasons.","ALL","18 Years","65 Years",{"count":76,"type":77},106,"ESTIMATED","INTERVENTIONAL",[80],"PHASE2","This study is to investigate the efficacy and safety of the induction chemotherapy + concurrent chemoradiotherapy（CCRT）combined with toripalimab and endostar treatment, in comparison with the induction chemotherapy + concurrent chemoradiotherapy（CCRT）, in treating locally advanced high-risk nasopharyngeal carcinoma",[83],"Nasopharyngeal Carcinoma","NOT_YET_RECRUITING","2020-06-24",{"date":87,"type":88},"2020-06-25","ACTUAL",{"date":90,"type":77},"2020-06",{"date":92,"type":77},"2026-06",{"name":5,"class":6}]